Talaris Therapeutics Inc. (TALS)
Company Description
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States.
The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders.
Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients.
The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders.
Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.
| Country | United States |
| IPO Date | May 7, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 84 |
| CEO | Mary Kay Fenton |
Contact Details
Address: 570 South Preston Street Louisville, Kentucky United States | |
| Website | https://talaristx.com |
Stock Details
| Ticker Symbol | TALS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001827506 |
| CUSIP Number | 87410C104 |
| ISIN Number | US89157D1054 |
| Employer ID | 00-0000000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Mary Kay Fenton | Interim Chief Executive Officer, Pres, Chief Financial Officer & Treasurer |
| Scott Requadt J.D., L.L.B., M.B.A., MBA | Pres, Chief Executive Officer, Sec. & Director |
| Michael Zdanowski | Chief Technology Officer |
| Andrew Clyde Farnsworth | Chief HR Officer |
| Colby Suire Ph.D. | Head of R&D |
| Courtney Wells | Senior Vice President of Clinical Operations |
| Devin Blass | Vice President of Technical Operations & Site Head |
| Dr. Suzanne T. Ildstad M.D. | Founder, Member of Scientific Advisory Board, Senior Scientific Advisor & Director |
| Eric Gornstein | Senior Vice President of Strategy |
| Farah Natoli | Head of Portfolio & Program Management |
| Nancy Krieger M.D. | Chief Medical Officer |
| Suzanne Tollerud | Vice President of Corporation Devel. |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 21, 2025 | ARS | Filing |
| Apr 21, 2025 | DEFA14A | Filing |
| Apr 21, 2025 | DEF 14A | Filing |
| Mar 13, 2025 | S-8 | Filing |
| Mar 13, 2025 | 10-K | Annual Report |
| Mar 13, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Feb 04, 2025 | 4 | Filing |
| Jan 29, 2025 | 4 | Filing |
| Jan 29, 2025 | 4 | Filing |